Back to Clinical Trials

Brief Title: Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)

INTRODUCTION

  • Org Study ID: G1T28-209
  • Secondary ID: N/A
  • NTC ID: NCT04887831
  • Sponsor: G1 Therapeutics, Inc.

BRIEF SUMMARY

This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer.

DETAILED DESCRIPTION

Patients will be randomly assigned (1:1) to receive standard of care platinum-based chemotherapy (with or without the addition of trilaciclib) administered intravenously (IV) in 21-day cycles followed by standard of care avelumab maintenance therapy (with or without the addition of trilaciclib) administered IV in 14-day cycles.

Patients enrolled in the study will be eligible to receive 4-6 cycles of platinum-based chemotherapy, and patients without progressive disease (PD) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines (i.e., with an ongoing complete response [CR], partial response [PR], or stable disease) after platinum-based chemotherapy will be eligible to receive avelumab maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, Investigator decision, or the end of the trial, whichever comes first.

Patients will be followed for survival approximately every 3 months after receiving the last dose of study medication.

  • Overall Status
    Recruiting
  • Start Date
    June 4, 2021
  • Phase
    Phase 2
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Progression-Free Survival

Primary Outcome 1 - Timeframe: From date of randomization until date of documented radiologic disease progression per RECIST v1.1 or death due to any cause, whichever comes first (on average 7 months)

CONDITION

  • Urothelial Carcinoma
  • Bladder Cancer
  • Myelosuppression Adult
  • Chemotherapy-induced Neutropenia
  • Metastatic Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
Age ≥18 years

- Histologically documented, locally advanced (T4b, any N; or any T, N 2-3) or metastatic urothelial carcinoma (M1, Stage IV)

- Measurable disease as defined by RECIST v1.1

- No prior systemic therapy in the inoperable, locally advanced, or metastatic setting including chemotherapy, immune checkpoint inhibitor therapy, targeted therapy, or investigational agents

- Archival tumor tissue must be available or a fresh biopsy must be obtained, unless approved by the Medical Monitor

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Adequate organ function as demonstrated by normal laboratory values
Exclusion Criteria:
Prior treatment with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or CD137 agonists, or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody (including ipilimumab), or any other therapeutic antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways in any setting

- Malignancies other than urothelial carcinoma within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason ≤6) prostate cancer on surveillance without any plans for treatment intervention (e.g., surgery, radiation, or castration)

- Presence of central nervous system (CNS) metastases/leptomeningeal disease requiring immediate treatment with radiation therapy or steroids.

- QTcF interval > 480 msec. For patients with ventricular pacemakers, QTcF > 500 msec

- Known hypersensitivity or allergy to avelumab, gemcitabine, cisplatin or carboplatin

- Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥3), any history of anaphylaxis, or uncontrolled asthma

- Prior hematopoietic stem cell or bone marrow transplantation, or solid organ transplantation

- Pregnant or lactating women

- Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
Current use of immunosuppressive medication, EXCEPT for the following:
Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)

- Systemic corticosteroids at physiological doses ≤10 mg/day of prednisone or equivalent

- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Clinical Contact

Role: Study Director

Affiliation: G1 Therapeutics, Inc.

Overall Contact

Name: Clinical Contact

Phone: 919-213-9835

Email: clinicalinfo@g1therapeutics.com

LOCATION

Facility Status Contact